Literature DB >> 31662548

Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer.

Jeeyeon Lee1, Won Hwa Kim2, Ji-Young Park3, Ho Yong Park4, Jin Hyang Jung1, Wan Wook Kim1, Chan Sub Park1, Ryu Kyung Lee1, Jee Young Park5, Yee Soo Chae6, Soo Jung Lee6, Hye Jung Kim2.   

Abstract

BACKGROUND/AIM: Multigene profiling assays provide strong evidence for predicting the prognosis of breast cancer. In this study, we aimed to evaluate the clinical validation of the BCT score with various prognostic factors.
MATERIALS AND METHODS: A total of 133 cases of hormone receptor-positive, cT1N0 breast cancers were analyzed. Risk stratification using the BCT score (Low, n=105; High, n=28) was analyzed with Ki67 index, p53 mutation, Immunohistochemistry 4 (IHC4) score, Nottingham Prognostic Index (NPI) and online PREDICT.
RESULTS: Ki67 index and NPI showed strong correlations with risk stratification based on BCT scores. Although the IHC4 score and online PREDICT were not associated with BCT score, there was a significant tendency of association with the online PREDICT results as the time of overall survival was increasing.
CONCLUSION: Risk classification based on BCT scores might have a clinical significance as a prognostic marker in hormone receptor-positive, HER2-negative, early breast cancer. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  BCT score; Breast; carcinoma; prognosis

Mesh:

Substances:

Year:  2019        PMID: 31662548      PMCID: PMC6899082          DOI: 10.21873/invivo.11714

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  28 in total

Review 1.  Significance of immunohistochemistry in breast cancer.

Authors:  Dana Carmen Zaha
Journal:  World J Clin Oncol       Date:  2014-08-10

2.  Personalized medicine in breast cancer: a systematic review.

Authors:  Sang-Hoon Cho; Jongsu Jeon; Seung Il Kim
Journal:  J Breast Cancer       Date:  2012-09-28       Impact factor: 3.588

3.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

Authors:  Jack Cuzick; Mitch Dowsett; Silvia Pineda; Christopher Wale; Janine Salter; Emma Quinn; Lila Zabaglo; Elizabeth Mallon; Andrew R Green; Ian O Ellis; Anthony Howell; Aman U Buzdar; John F Forbes
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

4.  Validity of the online PREDICT tool in older patients with breast cancer: a population-based study.

Authors:  N A de Glas; E Bastiaannet; C C Engels; A J M de Craen; H Putter; C J H van de Velde; A Hurria; G J Liefers; J E A Portielje
Journal:  Br J Cancer       Date:  2016-01-19       Impact factor: 7.640

5.  P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.

Authors:  Yunbao Pan; Yufen Yuan; Guoshi Liu; Yongchang Wei
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

6.  A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.

Authors:  Gyungyub Gong; Mi Jeong Kwon; Jinil Han; Hee Jin Lee; Se Kyung Lee; Jeong Eon Lee; Seon-Heui Lee; Sarah Park; Jong-Sun Choi; Soo Youn Cho; Sei Hyun Ahn; Jong Won Lee; Sang Rae Cho; Youngho Moon; Byung-Ho Nam; Seok Jin Nam; Yoon-La Choi; Young Kee Shin
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

7.  BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.

Authors:  Mi Jeong Kwon; Sae Byul Lee; Jinil Han; Jeong Eon Lee; Jong Won Lee; Gyungyub Gong; Peter D Beitsch; Seok Jin Nam; Sei Hyun Ahn; Byung-Ho Nam; Young Kee Shin
Journal:  PLoS One       Date:  2018-11-21       Impact factor: 3.240

8.  p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results.

Authors:  J Jacquemier; J P Molès; F Penault-Llorca; J Adélaide; M Torrente; P Viens; D Birnbaum; C Theillet
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

9.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

10.  The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis.

Authors:  P Yang; C W Du; M Kwan; S X Liang; G J Zhang
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.